Table 4.

Demographic and clinical characteristics of study participants by tertiles of augmentation index. Results are depicted as means ± standard deviation, median (interquartile range), or frequencies.

	Tertile 1 (< 4)	Tertile 2 (4–20)	Tertile 3 (> 20)	P (trend)
N	24	24	24
Age	58 ± 14	68 ± 9	66 ± 12	0.02
Female (%)	25	29	58	0.02
Black (%)	4	8	25	0.03
Creatinine Clearance (ml/min)	57 ± 22	47 ± 16	45 ± 18	0.03
Blood Pressure (mm Hg)
Systolic	129 ± 21	142 ± 18	148 ± 19	0.001
Diastolic	73 ± 10	76 ± 12	77 ± 9	0.29
Co-morbidities (%)
Hypertension	91	88	92	0.92
Diabetes	17	42	29	0.39
Prior cardiovascular disease	8	54	29	0.12
Medications (%)
ACE inhibitors	57	38	42	0.32
ARB	43	38	38	0.72
β-blockers	43	54	63	0.19
Serum Laboratory Data
Calcium (mg/dl)	9.7 ± 0.5	9.6 ± 0.4	9.5 ± 0.5	0.19
Phosphate (mg/dl)	2.9 ± 0.6	3.2 ± 0.6	3.0 ± 0.6	0.96
25-hydroxyvitamin D (ng/ml)	31 ± 11	31 ± 13	31 ± 15	0.94
1,25-dihydroxyvitamin D (pg/ml)	33 ± 14	31 ± 12	41 ± 15	0.05
Parathyroid hormone (pg/ml)	42 (23, 67)	52 (29, 128)	69 (39, 89)	0.12
Fibroblast growth factor 23 (RU/ml)	74 (35, 121)	110 (65, 159)	93 (52, 114)	0.23
Urine Laboratory Data
Urinary phosphate excretion (mg/d)	851 ± 373	661 ± 222	551 ± 191	<0.001
Urinary calcium excretion (mg/d)	87 ± 77	54 ± 42	64 ± 77	0.25